Jemperli(dostarlimab)
Jemperli (dostarlimab) is an antibody pharmaceutical. Dostarlimab was first approved as Jemperli on 2021-04-21. It has been approved in Europe to treat endometrial neoplasms. It is known to target programmed cell death protein 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Jemperli
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| jemperli | Biologic Licensing Application | 2024-08-01 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9272 | Injection, dostarlimab-gxly, 10 mg |
Clinical
Clinical Trials
83 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 13 | 14 | 2 | — | 1 | 27 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 4 | 7 | 2 | — | 1 | 12 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 7 | 4 | — | — | 11 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 3 | 6 | 2 | — | — | 9 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 1 | 4 | 2 | — | — | 7 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 4 | 2 | — | — | 7 |
| Head and neck neoplasms | D006258 | — | — | 1 | 4 | 1 | — | — | 5 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 3 | 1 | — | — | 4 |
| Squamous cell carcinoma | D002294 | — | — | 1 | 3 | 1 | — | — | 4 |
| Colonic neoplasms | D003110 | — | C18 | — | 2 | 1 | — | — | 3 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 4 | 9 | — | — | — | 10 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 2 | — | — | — | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 3 | — | — | — | 4 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | — | 4 | — | — | — | 4 |
| Adenocarcinoma | D000230 | — | — | — | 4 | — | — | — | 4 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 3 | — | — | — | 4 |
| Recurrence | D012008 | — | — | — | 4 | — | — | — | 4 |
| Sarcoma | D012509 | — | — | 1 | 2 | — | — | — | 3 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | 3 | — | — | — | 3 |
| Triple negative breast neoplasms | D064726 | — | — | — | 3 | — | — | — | 3 |
Show 33 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peritoneal neoplasms | D010534 | — | — | 1 | — | — | — | — | 1 |
| Kaposi sarcoma | D012514 | — | C46 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocarditis | D009205 | — | I51.4 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dostarlimab |
| INN | dostarlimab |
| Description | Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >7WSL:H|heavy chain
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLY
LQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG
ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHHHHH
>7WSL:L|light chain
DIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPSRFSGSGSGTEFTLTISSLQP
EDFATYYCQHYSSYPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 7WSL |
| CAS-ID | 2022215-59-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298124 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15627 |
| UNII ID | P0GVQ9A4S5 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PDCD1
PDCD1
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,526 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
658 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use